Back to top
more

Genomic Health, Inc. (GHDX)

(Delayed Data from NSDQ)

$67.55 USD

67.55
321,603

+1.67 (2.53%)

Updated May 3, 2019 04:00 PM ET

After-Market: $67.63 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

What's in the Cards for Genomic Health (GHDX) in Q4 Earnings?

by Zacks Equity Research

Similar to last quarter, Genomic Health (GHDX) is expected to gain from higher total product revenues in Q4.

    Genomic Health (GHDX) Oncotype DX GPS Test Results Positive

    by Zacks Equity Research

    Genomic Health's (GHDX) efforts to improve its prostate cancer business are encouraging.

      Quest Diagnostics to Buy MedXM, Boost Home Health Services

      by Zacks Equity Research

      Quest Diagnostics (DGX) actively pursues mergers and acquisitions to strengthen hold in the high-potential global home healthcare market.

        FDA Nod for QIAGEN's JAK2 Test Boosts Molecular Diagnostic

        by Zacks Equity Research

        QIAGEN (QGEN) strives to enhance Molecular Diagnostic segment, which was the highest revenue grosser in the last reported quarter.

          Innovation, Partnership Aid Genomic Health, Cost Woe Remains

          by Zacks Equity Research

          Genomic Health's (GHDX) recent positive finds from a string of 10 trials on Oncotype DX Breast Recurrence Score test are likely to buoy investors' optimism.

            Genomic Health at a 52-Week High: What's Driving the Stock?

            by Zacks Equity Research

            Genomic Health (GHDX) forges ahead with deals to strengthen hold in the high-potential prostate cancer therapeutics market.

              Genomic Health (GHDX) Oncotype DX Score Test Data Positive

              by Zacks Equity Research

              Genomic Health (GHDX) forges ahead with development of Oncotype DX Breast Recurrence Score test.

                Genomic Health-Janssen Pharma Tie Up, GPS Test in Focus

                by Zacks Equity Research

                Genomic Health (GHDX) focuses on notable partnerships to promote its Oncotype DX Genomic Prostate Score (GPS) test.

                  Genomic Health-Cleveland Diagnostics Deal to Boost Test Suite

                  by Zacks Equity Research

                  Genomic Health (GHDX) forges ahead with deals to strengthen hold in the high-potential prostate cancer therapeutics market.

                    Genomic Health Cancer Diagnostic Tests Grow Amid Cost Woes

                    by Zacks Equity Research

                    Revenues at Genomic Health (GHDX) improve year over year in Q3, driven by solid performances in the United States and internationally. However, rising operating losses continue to be a spoiler.

                      Genomic Health (GHDX) Swings to Earnings in Q3, Revenues Lag

                      by Zacks Equity Research

                      Genomic Health (GHDX) gains from strong adoption of its Oncotype DX test in Q3.

                        Genomic Health's Cost Pressure Mounts, Cancer Tests Strong

                        by Zacks Equity Research

                        Concerns related to Genomic Health's (GHDX) strong dependence on breast cancer tests still linger. Also, higher production cost and expenses continue to weigh heavily on the company's margins.

                          Genomic Health Ties up With Biocartis, Boosts Oncotype DX

                          by Zacks Equity Research

                          Genomic Health's (GHDX) agreement with Biocartis will provide Genomic Health rights to develop and commercialize its Oncotype DX Breast Recurrence Score test on the Idylla platform.

                            Genomic Health (GHDX) Posts Wider-than-Expected Loss in Q2

                            by Zacks Equity Research

                            Genomic Health (GHDX) continues to lag expectations despite strong adoption of its Oncotype DX test.

                              Can DENTSPLY Sirona (XRAY) Deliver a Beat in Q2 Earnings?

                              by Zacks Equity Research

                              DENTSPLY Sirona's (XRAY) results are likely to be boosted by surging dental & healthcare consumables space in the yet-to-be-reported second quarter.

                                Becton, Dickinson (BDX) Q2 Earnings: What's in the Cards?

                                by Zacks Equity Research

                                Becton, Dickinson's (BDX) second-quarter performance faces risks from unfavorable foreign exchange rate.

                                  Will Teladoc (TDOC) Pull Off a Surprise in Q2 Earnings?

                                  by Zacks Equity Research

                                  Teladoc's (TDOC) second-quarter earnings may be driven by higher revenues and increased membership, partly offset by an increase in operating expenses.

                                    Can Cardinal Health (CAH) Pull a Surprise in Q4 Earnings?

                                    by Zacks Equity Research

                                    Despite an upbeat outlook, cut-throat competition in the niche space and pricing pressure in generics portfolio are likely to mar Cardinal Health's (CAH) results in the fourth quarter.

                                      Genomic Health Cancer Tests Strong, Operating Expenses a Woe

                                      by Zacks Equity Research

                                      On Jun 19, we issued an updated research report on Redwood City, CA-based Genomic Health Inc (GHDX), a global cancer research company with a focus on advanced molecular diagnostics.

                                        Why Is Genomic Health (GHDX) Up 7.1% Since the Last Earnings Report?

                                        by Zacks Equity Research

                                        Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                          Genomic Health to Unveil Oncotype DX Study Results at ASCO

                                          by Zacks Equity Research

                                          Global cancer research company Genomic Health, Inc. (GHDX) will be presenting results from eight Oncotype DX studies at American Society of Clinical Oncology (ASCO) in Chicago.

                                            Genomic Health (GHDX) Looks Good: Stock Adds 5.2% in Session

                                            by Zacks Equity Research

                                            Genomic Health (GHDX) was a big mover last session, as the company saw its shares rise over 5% on the day amid huge volumes.

                                              Genomic Health Q1 Results Weak, Cancer Test Business Strong

                                              by Zacks Equity Research

                                              On May 16, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX).

                                                Genomic Health's (GHDX) Oncotype DX GPS Test Data Positive

                                                by Zacks Equity Research

                                                Genomic Health, Inc. (GHDX), a global cancer company, recently presented positive results for its Oncotype DX Genomic Prostate Score (GPS) test.

                                                  Genomic Health (GHDX) Misses Q1 Earnings & Sales Estimates

                                                  by Zacks Equity Research

                                                  Genomic Health, Inc. (GHDX) reported first-quarter 2017 loss per share of 7 cents, reflecting an improvement from the year-ago quarter's loss figure of 19 cents.